Xeris Biopharma Holdings Inc XERS
News
Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
Xeris Announces Details for XP-8121 Program Overview Webinar
Xeris Biopharma Reports Second Quarter 2026 Financial Results